Meloxicam SBEβCD Composition for Solubility and Rapid Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Meloxicam, a nonsteroidal anti-inflammatory drug, has poor aqueous solubility, leading to reduced bioavailability and slow onset of pain relief.
Innovation Solution
Formulating meloxicam with sulfobutyl ether β-cyclodextrin (SBEβCD) and bicarbonate to create an inclusion complex, enhancing solubility and bioavailability, and combining it with rizatriptan for rapid and sustained pain relief.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If meloxicam is administered alone, then the drug structure is simple, but the aqueous solubility is poor and bioavailability is reduced
Solution Approach 1:
The patent forms an inclusion complex between meloxicam and sulfobutyl ether β-cyclodextrin (SBEβCD). The cyclodextrin molecule creates a hydrophobic cavity that encapsulates the meloxicam molecule, forming a composite structure with improved aqueous solubility. This composite material approach resolves the contradiction by maintaining the therapeutic properties of meloxicam while dramatically improving its solubility and bioavailability characteristics.
Solution Approach 2:
SBEβCD acts as an intermediary carrier that facilitates the dissolution and absorption of meloxicam. The cyclodextrin forms a soluble complex in aqueous environments, serving as a mediator that transports the poorly soluble meloxicam through the gastrointestinal tract, thereby improving bioavailability without altering the active pharmaceutical ingredient itself.
2Speed
If meloxicam is administered alone, then the formulation is simple, but the onset of pain relief is slow
Solution Approach 1:
The inclusion complex formulation creates a composite material that enhances the dissolution rate of meloxicam. The cyclodextrin-meloxicam complex dissolves more rapidly in aqueous gastrointestinal fluids, leading to faster absorption and a quicker onset of analgesic effect, thereby resolving the contradiction between simple formulation and rapid onset.
Solution Approach 2:
The patent alters the physical-chemical parameters of meloxicam by forming an inclusion complex. This changes the solubility profile and dissolution kinetics of the drug, transforming it from a slowly dissolving solid to a rapidly dissolving complex, thereby accelerating the onset of pain relief without significantly complicating the formulation process.
3Reliability
If meloxicam is combined with SBEβCD and bicarbonate, then solubility and bioavailability increase, but the formulation complexity increases
Solution Approach 1:
The formulation creates a composite system comprising meloxicam, SBEβCD, and bicarbonate. The cyclodextrin forms the primary inclusion complex to enhance solubility, while bicarbonate serves as a pH-modifying excipient to maintain optimal dissolution conditions. This multi-component composite approach systematically addresses solubility and bioavailability challenges.
Solution Approach 2:
SBEβCD performs multiple functions: it forms the inclusion complex to enhance solubility, provides steric stabilization, and facilitates absorption. The bicarbonate component serves dual purposes of pH control and potential enhancement of drug dissolution. This multi-functionality reduces the need for additional excipients, thereby managing formulation complexity while achieving superior solubility and bioavailability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination significantly increases meloxicam's solubility and absorption rate, providing rapid and sustained pain relief, reducing the need for rescue medication and improving treatment outcomes in conditions like migraine and arthritis.
Implementation Method 1
Cyclodextrins can form complexes (i.e., an inclusion complex) with drugs by incorporating the drug into the center/hydrophobic portion of the cyclodextrin ring
Implementation Method 2
The combination of meloxicam with a sulfobutyl ether β-cyclodextrin (SBEβCD), a bicarbonate, and a rizatriptan significantly increases the solubility and absorption rate of the meloxicam
Data Source
AI summary
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.